TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24105031

Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 180 g/kg DM in feed block (FB)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 180 g/kg DM in FB
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 150 g/kg DM in FB
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: U‐cas supplementation at 120 g/kg DM in FB
Number of subjects: 4

Group type: COMPARATOR
Intervention: U‐cas supplementation at 0 g/kg DM in FB
Number of subjects: 4
Study: 22115931

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 848
Study: 20796154

Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrient (aminoleban EN)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard diet only
Number of subjects: 49
Study: 17425543

Group type: EXPERIMENTAL
Intervention: OASIS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyaloskin
Number of subjects: 0
Study: 16524150

Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Silicone membrane oxygenator
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Hollow fiber oxygenator (HFO)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Roller pumps
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Centrifugal pumps
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both roller and centrifugal pumps
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Perfusionists
Number of subjects: 94
Study: 11845362

Group type: EXPERIMENTAL
Intervention: Flashlamp‐pumped pulsed tunable dye laser (PDL) for port-wine stains (PWS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple pulse laser irradiation for hypertrophic PWS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early PDL therapy for capillary haemangiomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PDL treatment for mixed haemangiomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active intervention for life/organ-threatening lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasers for telangiectatic leg veins (TLV)
Number of subjects: 0
Study: 9856895

Group type: EXPERIMENTAL
Intervention: C-KIT+ cells in enteritis
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: C-KIT+ cells in NEC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 25
Study: 7610782

Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation (TENS) 90 Hz, 30 min, three times/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Flat occlusal splint (24 h/day)
Number of subjects: 31
Study: 2171853

Group type: EXPERIMENTAL
Intervention: Protein-rich meal (50 g of bovine serum albumin added)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Protein-free meal (3800 kJ energy content)
Number of subjects: 8
Study: 7274405

Group type: EXPERIMENTAL
Intervention: time-limited therapy of 6 sessions within 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: time-limited therapy of 12 sessions within 16 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: time-unlimited therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: waiting list control group
Number of subjects: 37
Study: 30422243

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks plus dacarbazine-matched placebo every 3 weeks)
Number of subjects: 418

Group type: COMPARATOR
Intervention: Dacarbazine (1000 mg/m2 every 3 weeks plus nivolumab-matched placebo every 2 weeks)
Number of subjects: 418
Study: 28954982

Group type: EXPERIMENTAL
Intervention: Intramuscle injection of testosterone enanthate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-administration (control)
Number of subjects: 0
Study: 25209610

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg three times daily) plus rifampicin (600 mg once a day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Linezolid (600 mg twice a day)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole and rifampicin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 150
Study: 24018206

Group type: EXPERIMENTAL
Intervention: WRITE Symptoms intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 21257057

Group type: EXPERIMENTAL
Intervention: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA) given subcutaneously every 12h for 10 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (0.5% of BSA in saline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GLP-2 (50 μg/kg of body weight of bovine GLP-2 in BSA)
Number of subjects: 8
Study: 19006643

Group type: EXPERIMENTAL
Intervention: Multimodal physical exercise program (6 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 20
Study: 17704418

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy regimens (including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel)
Number of subjects: 6642
Study: 15221881

Group type: EXPERIMENTAL
Intervention: Resistance training with creatine supplementation (5 g/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resistance training without creatine supplementation (placebo)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined groups (resistance training with and without creatine)
Number of subjects: 20
Study: 11848236

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltration
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Topical lignocaine/prilocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: No local treatment (Control)
Number of subjects: 90
Study: 9576390

Group type: EXPERIMENTAL
Intervention: RRV‐TV vaccine (titer 4 x 10(5) plaque‐forming units)
Number of subjects: 2282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2282
Study: 7872912

Group type: EXPERIMENTAL
Intervention: Isokinetic exercise (IKE)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isotonic exercise (ITE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No-exercise (NOE)
Number of subjects: 19
Study: 3188824

Group type: EXPERIMENTAL
Intervention: Pneumatic compression using inflatable leg splints
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no splints)
Number of subjects: 46
Study: 31564113

Group type: EXPERIMENTAL
Intervention: Participation in a nationwide education program
Number of subjects: 3585

Group type: EXPERIMENTAL
Intervention: Caring for at least 1 dying patient per month
Number of subjects: 3585

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 3585

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 3585

Group type: COMPARATOR
Intervention: Care staff
Number of subjects: 3585
Study: 29570598

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) - 3 sets of 10 repetitions of 8 whole-body exercises, with a 2-minute interval between sets.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control - stretching and relaxation exercises.
Number of subjects: 30
Study: 27142710

Group type: EXPERIMENTAL
Intervention: secukinumab 10 mg/kg
Number of subjects: 73

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 73
Study: 25708973

Group type: EXPERIMENTAL
Intervention: Liquid hand soap with 100 ppm MI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Liquid hand soap with 50 ppm MI
Number of subjects: 38

Group type: COMPARATOR
Intervention: Liquid hand soap without MI (negative control)
Number of subjects: 38
Study: 23611893

Group type: COMPARATOR
Intervention: CIND (n=92)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Dementia (n=59)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Control (n=158)
Number of subjects: 309

Group type: COMPARATOR
Intervention: CIND vs. Dementia
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 309
Study: 21908446

Group type: EXPERIMENTAL
Intervention: Fixed combination of 250 mg acetylsalicylic acid (ASA) + 200 mg paracetamol + 50 mg caffeine (Thomapyrin)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 18178197

Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 712

Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 712
Study: 16154315

Group type: EXPERIMENTAL
Intervention: Sterile gloves
Number of subjects: 275

Group type: COMPARATOR
Intervention: Clean gloves
Number of subjects: 275
Study: 15071269

Group type: EXPERIMENTAL
Intervention: Prophylactic ICD therapy
Number of subjects: 0
Study: 11084060

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) 5‐ to 10‐mg load, 1 to 4 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tacrolimus (TAC) therapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 14
Study: 9200324

Group type: EXPERIMENTAL
Intervention: Maximum compression bandage applied within 5 min of injury (mean = 2 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rest and elevation only, with some cases of non-maximum compression after 10-30 min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Strain injuries
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diagnostic ultrasound investigation
Number of subjects: 40
Study: 1348159

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (4 g daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Olsalazine (2 g daily)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Olsalazine
Number of subjects: 49
Study: 2938872

Group type: EXPERIMENTAL
Intervention: alpha h-ANP with angiotensin II
Number of subjects: 7

Group type: COMPARATOR
Intervention: Angiotensin II with placebo
Number of subjects: 7
Study: 31704473

Group type: EXPERIMENTAL
Intervention: Dried Grape Pomace (DGP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dried Citrus Pulp (DCP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 24
Study: 30056410

Group type: EXPERIMENTAL
Intervention: Manual Group (pressure maintained suboccipital inhibition technique)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Instrumental Group (self-treatment using an Occipivot cushion)
Number of subjects: 32
Study: 27028708

Group type: EXPERIMENTAL
Intervention: 5-day bright light exposure + environmental light (bright light exposure group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Environmental light alone (no intervention group)
Number of subjects: 55
Study: 24778002

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh) + conventional care
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional care only
Number of subjects: 28
Study: 22341193

Group type: EXPERIMENTAL
Intervention: Touch & Talk (T&T) - mothers touched, sang, or told stories or rhymes to their child during an invasive procedure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control - mothers did not have contact with their child during the invasive procedure
Number of subjects: 65
Study: 20190350

Group type: EXPERIMENTAL
Intervention: 9% CHO solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: 6.8% CHO plus 2.2% protein
Number of subjects: 12
Study: 18824675

Group type: EXPERIMENTAL
Intervention: CSF cytomorphology
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: PCR of rearranged immunoglobulin heavy‐chain genes in CSF
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Cranial MRI
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Any method (CSF cytomorphology, PCR, MRI)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: CSF pleocytosis (>5/microL)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: CSF protein
Number of subjects: 282
Study: 15693981

Group type: EXPERIMENTAL
Intervention: Futility stopping in clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12443833

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens 0.625 mg/day (ERT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with 5 mg/day continuous medroxyprogesterone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ERT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ERT and HRT
Number of subjects: 40
Study: 10885835

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B
Number of subjects: 46

Group type: COMPARATOR
Intervention: Alcoholic liver cirrhosis
Number of subjects: 46
Study: 8562470

Group type: EXPERIMENTAL
Intervention: slow-release verapamil 240 mg once daily
Number of subjects: 1464

Group type: COMPARATOR
Intervention: chlorthalidone 25 mg once daily
Number of subjects: 1464

Group type: EXPERIMENTAL
Intervention: captopril 25 mg daily (for nonresponders)
Number of subjects: 1464
Study: 2292349

Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg t.i.d. for 8 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 7455836

Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-acting benzodiazepines
Number of subjects: 0
Study: 31039280

Group type: EXPERIMENTAL
Intervention: Ketone ester (KE)
Number of subjects: 18
Study: 28417318

Group type: EXPERIMENTAL
Intervention: Brenzys autoinjector
Number of subjects: 191
Study: 25433464

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 60
Study: 22309885

Group type: EXPERIMENTAL
Intervention: BWL + H
Number of subjects: 201

Group type: COMPARATOR
Intervention: BWL
Number of subjects: 201
Study: 23896782

Group type: EXPERIMENTAL
Intervention: Thumb-Index Finger Method (TIFM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two Finger Method (TFM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Two-Thumb Encircling Hands Method (TTEM)
Number of subjects: 60
Study: 19821224

Group type: EXPERIMENTAL
Intervention: Hyperoxia training (supplemental oxygen during training)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxia training (ambient air during training)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hyperoxia training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxia training
Number of subjects: 12
Study: 16741306

Group type: EXPERIMENTAL
Intervention: Automated algorithm for SPECT analysis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional visual assessment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combined visual and automated approach
Number of subjects: 53
Study: 14672645

Group type: EXPERIMENTAL
Intervention: REACT intervention strategies including community organization, public education, professional education, and patient education.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison communities (control group).
Number of subjects: 20
Study: 11606347

Group type: EXPERIMENTAL
Intervention: Modified Trendelenburg position
Number of subjects: 739

Group type: COMPARATOR
Intervention: Horizontal position
Number of subjects: 739
Study: 9675626

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg/2 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pentazocine (30 mg/mL)
Number of subjects: 50
Study: 8129120

Group type: EXPERIMENTAL
Intervention: Thoracic epidural sufentanil 50 micrograms
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lumbar epidural sufentanil 50 micrograms
Number of subjects: 30
Study: 2572618

Group type: EXPERIMENTAL
Intervention: Midaglizole (200 mg)
Number of subjects: 17
Study: 1101099

Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 50

Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 50
Study: 31238414

Group type: EXPERIMENTAL
Intervention: Anterior Chamber Maintainer (ACM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Phacosandwich
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fishhook
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Irrigating Vectis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Viscoexpression
Number of subjects: 200
Study: 28185899

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy (20-80 mg/day) for 6 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 34
Study: 25305567

Group type: EXPERIMENTAL
Intervention: MenACWY‐TT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coad (MenACWY‐TT co-administered with DTaP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HibMenCY‐TT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (DTaP at 15-18 months)
Number of subjects: 0
Study: 23566694

Group type: EXPERIMENTAL
Intervention: Systemic enzyme therapy (twice-daily dose for 5 days starting from the first postoperative day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study: 21285229

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation with 50 mg elemental iron for 14 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 19125084

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with GaAlAs, wavelength 830 nm, power 100 mW, dose 4 J/cm, for 5 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 21
Study: 16633139

Group type: EXPERIMENTAL
Intervention: Reboxetine 8‐10 mg per day
Number of subjects: 357

Group type: COMPARATOR
Intervention: Citalopram 20‐40 mg per day
Number of subjects: 357
Study: 15256389

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone
Number of subjects: 3421

Group type: COMPARATOR
Intervention: fluticasone
Number of subjects: 3421
Study: 11399688

Group type: EXPERIMENTAL
Intervention: Salmeterol plus theophylline
Number of subjects: 943

Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 943
Study: 9357590

Group type: EXPERIMENTAL
Intervention: Computer system for automatic stenosis detection and quantification
Number of subjects: 49

Group type: COMPARATOR
Intervention: Individual radiologists
Number of subjects: 49
Study: 8106898

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic and anti-platelet therapy
Number of subjects: 0
Study: 3605188

Group type: EXPERIMENTAL
Intervention: Combined therapy of NPH and tolazamide
Number of subjects: 12

Group type: COMPARATOR
Intervention: NPH alone
Number of subjects: 12
Study: 30856112

Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: National Institute on Aging (NIA) recommended diet
Number of subjects: 27
Study: 27988420

Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV)
Number of subjects: 3473

Group type: COMPARATOR
Intervention: Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV) with abnormal LBC and HPV 16/18/45
Number of subjects: 3473

Group type: COMPARATOR
Intervention: Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2) with abnormal cytology or HPV persistence for 12 months
Number of subjects: 3473

Group type: EXPERIMENTAL
Intervention: Aptima HPV Assay (AHPV) and Hybrid Capture® 2 High‐Risk HPV DNA Test® (HC2)
Number of subjects: 3473
Study: 26667262

Group type: EXPERIMENTAL
Intervention: Aflibercept and Bromfenac
Number of subjects: 27

Group type: COMPARATOR
Intervention: Aflibercept only (Control)
Number of subjects: 27
Study: 23361101

Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (four types), ingested three times daily for 3 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (four types)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements (two types)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ephedra-free dietary supplements
Number of subjects: 12
Study: 21145532

Group type: EXPERIMENTAL
Intervention: Twice-daily, preservative-free ketorolac 0.45%
Number of subjects: 511

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 511
Study: 18445111

Group type: EXPERIMENTAL
Intervention: Alcohol (male: 0.6 g/kg, female: 0.5 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 20
Study: 17135158

Group type: EXPERIMENTAL
Intervention: Dysmo-off (5 g twice daily for 4 days, one day prior to and three days after menstruation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac sodium (50 mg twice daily for 4 days, one day prior to and three days after menstruation)
Number of subjects: 120
Study: 12665490

Group type: EXPERIMENTAL
Intervention: 192Ir with 15 Gy at 2 mm from the source axis
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 192Ir with 18 Gy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10742724

Group type: EXPERIMENTAL
Intervention: Indinavir alone (800 mg q8h)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Indinavir plus zidovudine
Number of subjects: 996

Group type: COMPARATOR
Intervention: Zidovudine alone (200 mg q8h)
Number of subjects: 996
Study: 8650247

Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined use of other agents along with vitamin D
Number of subjects: 0
Study: 1666199

Group type: EXPERIMENTAL
Intervention: Adinazolam
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6352611

Group type: EXPERIMENTAL
Intervention: 1-g intramuscular ceftazidime
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2-g intramuscular ceftazidime (twice or thrice daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ceftazidime (general outcome)
Number of subjects: 72
Study: 31724291

Group type: EXPERIMENTAL
Intervention: Animal-assisted therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Mandala painting
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 30204523

Group type: EXPERIMENTAL
Intervention: Higher-intensity taper (5.9% increase in intensity)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Lower-intensity taper (8.5% decrease in intensity)
Number of subjects: 11